These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
256 related articles for article (PubMed ID: 10219819)
1. Role of p53 assessment in management of Barrett's esophagus. Kubba AK; Poole NA; Watson A Dig Dis Sci; 1999 Apr; 44(4):659-67. PubMed ID: 10219819 [TBL] [Abstract][Full Text] [Related]
2. p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus. Bian YS; Osterheld MC; Bosman FT; Benhattar J; Fontolliet C Mod Pathol; 2001 May; 14(5):397-403. PubMed ID: 11353048 [TBL] [Abstract][Full Text] [Related]
3. Predictors of progression in Barrett's esophagus II: baseline 17p (p53) loss of heterozygosity identifies a patient subset at increased risk for neoplastic progression. Reid BJ; Prevo LJ; Galipeau PC; Sanchez CA; Longton G; Levine DS; Blount PL; Rabinovitch PS Am J Gastroenterol; 2001 Oct; 96(10):2839-48. PubMed ID: 11693316 [TBL] [Abstract][Full Text] [Related]
4. Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases. Schneider PM; Casson AG; Levin B; Garewal HS; Hoelscher AH; Becker K; Dittler HJ; Cleary KR; Troster M; Siewert JR; Roth JA J Thorac Cardiovasc Surg; 1996 Feb; 111(2):323-31; discussion 331-3. PubMed ID: 8583805 [TBL] [Abstract][Full Text] [Related]
5. TP53 gene mutations are rare in nondysplastic Barrett's esophagus. Novotna K; Trkova M; Pazdro A; Smejkal M; Soukupova A; Kodetova D; Smejkal P; Sedlacek Z Dig Dis Sci; 2006 Jan; 51(1):110-3. PubMed ID: 16416221 [TBL] [Abstract][Full Text] [Related]
6. p53 immunoreactivity in Barrett's metaplasia, dysplasia, and adenocarcinoma--a case report. Kimura H; Konishi K; Kaji M; Maeda K; Yabushita K; Miwa A Hepatogastroenterology; 2001; 48(42):1662-4. PubMed ID: 11813596 [TBL] [Abstract][Full Text] [Related]
7. Adenocarcinoma arising in Barrett's oesophagus: evidence for the participation of p53 dysfunction in the dysplasia/carcinoma sequence. Hardwick RH; Shepherd NA; Moorghen M; Newcomb PV; Alderson D Gut; 1994 Jun; 35(6):764-8. PubMed ID: 8020801 [TBL] [Abstract][Full Text] [Related]
8. p53-mutant clones and field effects in Barrett's esophagus. Prevo LJ; Sanchez CA; Galipeau PC; Reid BJ Cancer Res; 1999 Oct; 59(19):4784-7. PubMed ID: 10519384 [TBL] [Abstract][Full Text] [Related]
9. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus. Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797 [TBL] [Abstract][Full Text] [Related]
10. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis. Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402 [TBL] [Abstract][Full Text] [Related]
11. Clinical implications of p53 gene mutation in the progression of Barrett's epithelium to invasive esophageal cancer. Casson AG; Manolopoulos B; Troster M; Kerkvliet N; O'Malley F; Inculet R; Finley R; Roth JA Am J Surg; 1994 Jan; 167(1):52-7. PubMed ID: 8311140 [TBL] [Abstract][Full Text] [Related]
12. Risk factors, DNA damage, and disease progression in Barrett's esophagus. Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340 [TBL] [Abstract][Full Text] [Related]
13. Mutation analysis of the p53, APC, and p16 genes in the Barrett's oesophagus, dysplasia, and adenocarcinoma. González MV; Artímez ML; Rodrigo L; López-Larrea C; Menéndez MJ; Alvarez V; Pérez R; Fresno MF; Pérez MJ; Sampedro A; Coto E J Clin Pathol; 1997 Mar; 50(3):212-7. PubMed ID: 9155671 [TBL] [Abstract][Full Text] [Related]